- 作者： Yu-Shiuan Wang, Monika Kumari, Guan-Hong Chen, Ming-Hsiang Hong, Joyce Pei-Yi Yuan, Jui-Ling Tsai & Han-Chung Wu
- 作者服務機構： 1.Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei, 11571, Taiwan 2.Institute of Cellular and Organismic Biology, Academia Sinica, No. 128, Academia Road, Section 2, Nankang, Taipei, 11529, Taiwan
- 中文摘要：
- 英文摘要：
mRNA-based drugs have tremendous potential as clinical treatments, however, a major challenge in realizing this drug class will promise to develop methods for safely delivering the bioactive agents with high efficiency and without activating the immune system. With regard to mRNA vaccines, researchers have modified the mRNA structure to enhance its stability and promote systemic tolerance of antigenic presentation in non-inflammatory contexts. Still, delivery of naked modified mRNAs is inefficient and results in low levels of antigen protein production. As such, lipid nanoparticles have been utilized to improve delivery and protect the mRNA cargo from extracellular degradation. This advance was a major milestone in the development of mRNA vaccines and dispelled skepticism about the potential of this technology to yield clinically approved medicines. Following the resounding success of mRNA vaccines for COVID-19, many other mRNA-based drugs have been proposed for the treatment of a variety of diseases. This review begins with a discussion of mRNA modifications and delivery vehicles, as well as the factors that influence administration routes. Then, we summarize the potential applications of mRNA-based drugs and discuss further key points pertaining to preclinical and clinical development of mRNA drugs targeting a wide range of diseases. Finally, we discuss the latest market trends and future applications of mRNA-based drugs. - 中文關鍵字：
- 英文關鍵字： mRNA vaccine, mRNA therapeutics, Lipid nanoparticles, Targeting mRNA delivery system, Administration routes
